Endo gets US approval for long-acting testosterone



Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

WASHINGTON (AP) — Drugmaker Endo Pharmaceuticals says it received U.S. approval for its long-acting testosterone injection Aveed, which joins a crowded field of hormone-boosting drugs for men.

The Irish drugmaker said the Food and Drug Administration approved the drug to treat men with low testosterone, which is often associated with fatigue, weight gain and low libido. Endo's injection is to be taken once every 10 weeks, versus weekly or biweekly dosing for older products.

The FDA approval comes amid growing scrutiny of popular testosterone drugs.

In January the FDA said it was reviewing the safety of the drugs after a 45,000-patient study suggested testosterone therapy could double the risk of heart attack in men 65 and older. Last month the consumer advocacy group Public Citizen called for a bold warning on the drugs.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast